Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06663722 · ClinicalTrials.gov registry record · Phase 2

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease and cGVHD, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
49
Enrollment target
1
Study location

NCT06663722 is a Phase 2 study of Chronic Graft Versus Host Disease and cGVHD that is actively recruiting participants, run by University of Miami. The registered enrollment target is 49 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06663722, a Phase 2 study of Chronic Graft Versus Host Disease and cGVHD, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).

Interventions

  • BIOLOGICAL Axatilimab
  • PROCEDURE Extracorporeal Photopheresis

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2025-05-05
Est. Completion 2030-05-05
Phase Phase 2

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT06663722

The ClinicalTrials.gov registry entry for NCT06663722 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Axatilimab is the first listed.

NCT06663722 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06663722 about?

NCT06663722 is a clinical study titled "Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease". The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).

What is the current status of trial NCT06663722?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2025-05-05. Estimated completion is 2030-05-05.

What conditions does trial NCT06663722 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease, cGVHD.

What interventions are being tested in trial NCT06663722?

The interventions under investigation include: Axatilimab (BIOLOGICAL), Extracorporeal Photopheresis (PROCEDURE).

Who is sponsoring clinical trial NCT06663722?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06663722 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.